Your browser doesn't support javascript.
loading
Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models.
Wang, Feng; Tsai, Jordan C; Davis, Jonathan H; Chau, Bryant; Dong, Jia; West, Sean M; Hogan, Jason M; Wheeler, Matthew L; Bee, Christine; Morishige, Winse; Cayton, Thomas; David-Brown, Donata; Zhang, Chengyue; Kozhich, Alexander; Sproul, Tim; Dollinger, Gavin; Rajpal, Arvind; Strop, Pavel.
Afiliación
  • Wang F; Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
  • Tsai JC; Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
  • Davis JH; Invenra, Inc, Madison, WI, USA.
  • Chau B; Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
  • Dong J; Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
  • West SM; Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
  • Hogan JM; Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
  • Wheeler ML; Immuno-Oncology Research, Bristol-Myers Squibb, Redwood City, CA, USA.
  • Bee C; Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
  • Morishige W; Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
  • Cayton T; Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
  • David-Brown D; Bioanalytical Sciences, Bristol-Myers Squibb, Princeton, NJ, USA.
  • Zhang C; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Redwood City, CA, USA.
  • Kozhich A; Bioanalytical Sciences, Bristol-Myers Squibb, Princeton, NJ, USA.
  • Sproul T; Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
  • Dollinger G; Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
  • Rajpal A; Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
  • Strop P; Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
MAbs ; 12(1): 1685350, 2020.
Article en En | MEDLINE | ID: mdl-31856660
The development of antibody therapeutics relies on animal models that accurately recapitulate disease biology. Syngeneic mouse models are increasingly used with new molecules to capture the biology of complex cancers and disease states, and to provide insight into the role of the immune system. The establishment of syngeneic mouse models requires the ability to generate surrogate mouse counterparts to antibodies designed for humans. In the field of bispecific antibodies, there remains a dearth of technologies available to generate native IgG-like mouse bispecific antibodies. Thus, we engineered a simple co-expression system for one-step purification of intact mouse IgG1 and IgG2a bispecific antibodies from any antibody pair. We demonstrated proof of concept with CD3/CD20 bispecific antibodies, which highlighted both the quality and efficacy of materials generated by this technology.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Linfocitos T / Ingeniería de Proteínas / Anticuerpos Biespecíficos / Rituximab Límite: Animals Idioma: En Revista: MAbs Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Linfocitos T / Ingeniería de Proteínas / Anticuerpos Biespecíficos / Rituximab Límite: Animals Idioma: En Revista: MAbs Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos